Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 66, Issue 2, 2004, Pages 193-201

  Raslova K ^a,f   Bogoev, M ^b   Raz, I ^c   Leth, G ^d   Gall, M A ^d   Hancu N ^e  

^a INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

^b Clinic of Endocrinology and Metabolic Disorders   (Macedonia)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d NOVO NORDISK A S   (Denmark)

^e Diabetes Center and Clinic   (Romania)

^f NONE

Author keywords

Insulin aspart; Insulin detemir; Type 2 diabetes; Variation in FPG; Weight

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; ISOPHANE INSULIN; NEUTRAL INSULIN;

ADULT; AGED; ARTICLE; BREAST ABSCESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC COMA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN ALLERGY; STATISTICAL SIGNIFICANCE; WEIGHT GAIN;

EID: 6944244979     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2004.03.003     Document Type: Article

References (37)

1. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. 321:2000;405-412
2. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28:1995;103-117
3. Gaede P., Vedel P., Larsen N., Jensen G., Parving H-H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348:2003;383-393
4. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int. J. Obes. 26:2002;S18-S24
5. Guthrie R. Is there a need for a better basal insulin? Clin. Diabetes. 19:2001;66-70
6. White J.R., Campbell R.K. Recent developments in the pharmacological reduction of blood glucose in patients with type 2 diabetes. Clin. Diabetes. 19:2001;153-159
7. Starke A., Heinemann L., Hohlmann A., Berger M. The action profiles of human NPH insulin preparations. Diabetes Med. 6:1989;239-244
8. Kølendorf K., Bojsen J., Deckert T. Clinical factors influencing the absorption of 125I-NPH insulin in diabetic patients. Horm. Metab. Res. 15:1993;274-278
9. Jehle P.M., Micheler C., Jehle D.R., Breitig D., Boehm B.O. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet. 354:1999;307-335
10. Kurtzhals P., Havelund S., Jonassen I., et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 312:1995;725-731
11. Pieber T.R., Plank J., Goerzer E., et al. Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with type 1 diabetes. Diabetes. 51(Suppl 2):2002;A53
12. Whittingham J.L., Havelund S., Jonassen I. Crystal structure of a prolonged-acting insulin with albumin-binding properties. Biochemistry. 36:1997;2826-2831
13. Markussen J., Havelund S., Kurtzhals P., et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia. 39:1996;281-288
14. Vague P., Selam J.L., Skeie S., et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 26:2003;590-596
15. Hermansen K., Madsbad S., Perrild H., Kristensen A., Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin. Diabetes Care. 24:2001;296-301
16. T. Heise, L. Nosek, B. Biilmann Rønn, L. Endahl, L. Heinemann, C. Kapitza, E. Draeger, Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with Type 1 diabetes, Diabetes (in press).
17. P. Home, P. Bartley, D. Russell-Jones et al. Insulin detemir offers improved glycemic control compared to NPH insulin in people with Type 1 diabetes a randomized clinical trial, Diabetes Care 27 (5) (2004).
18. T. Haak, A. Tiengo, E. Draeger, M. Suntum, W. Waldhäusl, Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with Type 2 diabetes, Diabetes Obes. Metab. (in press).
19. Standl E., Roberts A., Lang H. One-year safety and efficacy of insulin detemir in subjects with type 1 diabetes. Favourable weight development and risk reduction of nocturnal hypoglycaemia compared to NPH. Diabetologia. 45(Suppl. 2):2002;A51
20. International Conference of Harmonisation (ICH), Topic E6: Harmonised tripartite guidelines for good clinical practice, Step 5, Consolidated Guideline 1.5.96.
21. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Last amended by the 52nd WMA General Assembly, Edinburg, Scotland, October 2000.
22. Muggeo M., Verlato G., Boncra E., Zoppini G., Corbellini M., de Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona diabetes study. Circulation. 96:1997;1750-1754
23. Roberts A., Bayer T., Munksgaard E., Lang H., Standl E. Efficacy and safety of 6-month treatment with insulin detemir in type 1 diabetic patients on a basal/bolus regimen. Diabetes. 50(Suppl. 2):2001;A129
24. Strange P., McGill J., Mazzeo M. Reduced pharmacokinetic (PK) variability of a novel, long-acting insulin analog. Diabetes. 48(Suppl. 1):1999;A103
25. D. Russell-Jones, R. Simpson, B. Hylleberg, E. Draeger, J. Bolinder, Effects of once-daily insulin detemir or NPH on blood glucose control in people with type 1 diabetes using a basal-bolus regimen, Clin. Ther. (in press).
26. Home P.D., Lindholm A., Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diab. Med. 17:2002;762-770
27. Heller S.R. Reducing hypoglycaemia with insulin analogues. Int. J. Obes. 26(Suppl. 3):2002;S31-S36
28. I.F. Douek, E.A.M Gale, The problem of weight gain on insulin, in: A.H. Barnett (Ed.), Insulin Made Easy, Medical Education Partnership, London, UK, 2001, pp. 80-89.
29. Everson S.A., Goldberg D.E., Helmrich S.P., et al. Weight gain and the risk of developing insulin resistance syndrome. Diabetes Care. 21:1998;1637-1643
30. Wilkin T.J. The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. Diabetologia. 44:2001;914-922
31. Diabetes Control and Complications Trial Research Group, Adverse events and their association with treatment regimens in the diabetes control and complications trial, Diabetes Care 18 (1995) 1415-1427.
32. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 12 (1998) 837-853.
33. I. De Leeuw, P. Vague, J.-L. Selam, S. Skeie, H. Lang, E. Draeger, J.W.F. Elte, Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin, Diabetes Obes. Metab. (in press).
34. Rafkin-Mervis L.E., Marks J.B. The science of diabetic snack bars: a review. Clin. Diabetes. 19:2001;4-12
35. The DCCT Research Group, Weight gain associated with intensive therapy in the diabetes control and complications trial, Diabetes Care 11 (1998) 567-573.
36. American Diabetes Association, Standards of medical care for patients with diabetes mellitus, Diabetes Care 26 (2003) S33-S50.
37. Rosenstock J., Schwartz S.L., Clark C.M., Park G.D., Donley D.W., Edwards M.B. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 24:2001;631-636